TQC3721 + glyberlam

TQC3721 is a novel inhaled dual phosphodiesterase 3 and 4 (PDE3/4) inhibitor developed by Chia Tai Tianqing Pharmaceutical Group (a subsidiary of Sino Biopharmaceutical) for the treatment of chronic obstructive pulmonary disease (COPD). It is a small molecule therapeutic designed to provide both bronchial smooth muscle relaxation (bronchodilation) and anti-inflammatory effects by simultaneously inhibiting the PDE3 and PDE4 enzymes. As of mid-2026, TQC3721 is in Phase III clinical development for its nebulized suspension formulation and has been licensed to AstraZeneca for development and commercialization outside of China. The specific combination 'TQC3721 + glyberlam' is not a recognized pharmaceutical product; 'glyberlam' appears to be an unverified or misspelled name, possibly intended to refer to a long-acting muscarinic antagonist (LAMA) such as glycopyrronium, which is commonly used in combination therapies for COPD.